AstraZeneca India has laid off over 125 employees in its biopharmaceutical business unit, including senior managers and sales executives. The job cuts are part of a strategic restructuring due to loss of patent exclusivity and competition from generic drugs. The company continues to focus on new patented drugs for specialized treatments.
